INFORMATION DISCLOSURE STATEMENT BY APPLICANT Application Application of the statement of

	FILED VIA EPS
Attorney Docket Number	4239-67016-02
Application Number	10/532,374
Filing Date	April 21, 2005
First Named Inventor	Berzofsky
Art Unit	1643
Examiner Name	Sheela J. Huff

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending material amplications, provide the another amplication control.

Examiner's Initials*	Cite No. (optional)	Number	Date	Name of Applicant or Patentee
		6,855,507	02/15/2005	Chugai Seiyaku Kabushiki Kaisha

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Date	Name of Applicant or Patentee
		JP	11-201967	01/14/1998	Chugai Pharmaceutical Co. Ltd.
		WIPO	99/40220	08/12/1999	Glaxo Group Limited
		WIPO	01/16604	03/08/2001	Signal Pharmaceuticals, Inc.
		WIPO	01/74404	10/11/2001	Novarx
		JP	2002-506613	03/05/2002	Glaxo Group Limited
		JP	2003-508755	03/04/2003	Signal Pharmaceuticals, Inc.
		JP	2003-528930	09/30/2003	Novarx

EXAMINER SIGNATURE:	DATE CONSIDERED:
* E	

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.